No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 22 of the 40 quarters in the window, leaving 18 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Vivani Medical, Inc. (VANI) stock was $1.24 as of Oct 6, 2026, 4:00 PM EDT, up 1.64% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -12.8% · 3-year avg +6.8%/yr · 5-year avg -32.7%/yr
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases.
Biotechnology · Alameda, CA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.07
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.07
vs Estimate
$-0.08
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1VANI | $106.93M | $1.24 | +1.64% | -12.80% | -32.72% | -34.24% | N/A |
| 2OTLK | $106.96M | $0.57 | -3.95% | -43.67% | -57.40% | -50.38% | vs VANI |
| 3CPIX | $106.98M | $7.14 | +0.71% | +172.53% | +25.62% | +5.52% | vs VANI |
| 4CRBP | $107.09M | $5.78 | -1.20% | -60.38% | -28.32% | -31.74% | vs VANI |
| 5APYX | $107.17M | $2.54 | -2.12% | -10.07% | -28.10% | N/A | vs VANI |
| 6IMUX | $106.52M | $7.82 | -3.10% | -17.41% | -35.70% | -43.80% | vs VANI |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$3.83
+209.1% upside
Low
$3.50
Current
$1.24
High
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Quarter ending Dec 2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Quarter ending Mar 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Quarter ending Jun 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.32 | $-0.32 | $-0.32 | 1 |
| FY 2027 | $-0.39 | $-0.39 | $-0.39 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
